slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 65,611-65,640
Pages 3,679
Rows per page 30
Component
65,611-65,640 of 110,355
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
36
The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a matrix-like layout to categorize drugs by disease area and development stage (marketed, late-stage, early-stage).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
41
The slide uses a timeline-based map visualization to illustrate market penetration goals.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
44
The slide uses a bridge metaphor to represent the collaboration between the two entities.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
45
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
47
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
02
Includes a specific date note at the bottom: September 9th, 2022.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list to present key company highlights.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
06
The slide uses a Gantt-style visualization to show progress through Preclinical, Phase 1, and Phase 2 stages for multiple assets.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
07
The slide uses a hub-and-spoke diagram to represent the platform model.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
Slide 09 of the deck.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
11
Uses a split-layout: left side provides market context/sizing, right side provides clinical pain points.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a line chart to demonstrate clinical efficacy over 12 weeks compared to baseline.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide combines a product summary table on the left with a clinical trial line chart on the right.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
15
The slide uses chemical structures and bar charts to demonstrate the superiority of R-ketamine over S-ketamine.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
16
CADSS = Clinician Administered Dissociative States Scale. Data points represent individual patient scores over time.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
17
The slide outlines a clinical trial protocol for a drug candidate (PCN-101) targeting Treatment-Resistant Depression (TRD).ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
18
The slide uses a feature-comparison matrix to highlight differentiation in mechanism, duration, and distribution.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
22
Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
23
The slide highlights efficacy in cognitive endpoints for a specific patient population (DPNP).ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit